Meet the Visionary Steering Edesa Biotech’s Future: A Transformative Leadership Change
Peter J. Weiler joins Edesa Biotech as Chief Financial Officer in May, marking a pivotal transition for the company and the broader biotech industry. Weiler brings extensive experience from Exzell…
The New Financial Architect: Transforming the Future of Edesa Biotech
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux. Weiler's extensive background spans key roles at Exzell Pharma, Biosyent Inc.,…
A New Era at Edesa Biotech: The Bold Leadership Shift Shaping Its Future
Peter J. Weiler appointed as new CFO of Edesa Biotech, starting May 1, 2025. Weiler brings extensive experience, with previous roles at Exzell Pharma and Biosyent Inc. Weiler holds an…
A Key Leadership Change at Edesa Biotech: What Peter J. Weiler Brings to the Table
A pivotal leadership change occurs at Edesa Biotech as Peter J. Weiler is appointed CFO, bringing extensive experience in business development and pharmaceutical leadership. Weiler's background includes key roles at…
Biotech Transformation: Edesa Welcomes New CFO with a Strategic Edge
Peter J. Weiler joins Edesa Biotech as CFO on May 1, 2025, bringing extensive leadership in biotechnology and pharmaceuticals. Weiler's experience includes roles as President of Exzell Pharma and VP…
Edesa Biotech’s Strategic Shift: What the New CFO Means for Their Future
Edesa Biotech appoints Peter J. Weiler as the new CFO, effective May 1, 2025, signaling a strategic shift. Weiler brings a robust track record in biotech and pharma, previously leading…
How a Groundbreaking Biotech Partnership is Set to Revolutionize mRNA Therapies
Wacker Biotech and RNAV8 Bio have formed a strategic alliance to advance mRNA-based therapies. The partnership combines Wacker’s biopharma manufacturing expertise with RNAV8’s mRNA engineering capabilities. Focus is placed on…
The Game-Changing CFO Appointment at Edesa Biotech: A New Era in Finance and Strategy
Edesa Biotech has appointed Peter J. Weiler as the new Chief Financial Officer, marking a pivotal moment for the company's growth and innovation. Weiler brings extensive experience in the pharmaceutical…
The Power Shift at Edesa Biotech: A CFO’s Exit and a New Leader’s Promise
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Unlocking the Future of Medicine: A Revolutionary mRNA Partnership
Wacker Biotech and RNAV8 Bio have embarked on a transformative mRNA technology partnership, aiming to revolutionize medicine. Wacker Biotech brings advanced microbial fermentation capabilities, enhancing pharmaceutical protein and pDNA production.…